comprehensive -WSS

comprehensive

author：explore 2025-10-01 18:07:11 - browse：42388

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Experimental asthma app from Apple and Anthem shows promise

explore

WSS

FDA approves Sage Therapeutics’ rapid

2 officers injured in shooting in Orlando, police say

How state and local governments are sidelining science

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Personalized medicine goes far beyond genetics

entertainment

comprehensive

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Heart disease in astronauts blamed on cosmic radiation

In age of alternative facts, a scholarly course on calling out crap

Group behind ProMed defends move to subscription

Psychedelics group wrestles with new pharma identity

Experimental asthma app from Apple and Anthem shows promise

Bright Health sells Medicare Advantage business to Molina

Medicare’s new pay boost for primary care is angering specialists

The cancer drug shortage isn’t new — and neither are the solutions

Medical school prerequisites are outdated

hotspot

Physicians aren't 'burning out.' They're suffering from moral injury

What health policies could hitch a ride on a spending bill?

Healthy food access boosts outcomes in two studies

Publishing genetic code of viruses could cause disaster

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Chris Christie meets with Zelenskyy during Ukraine trip

knowledge

explore

explore

explore